JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carlsson, L.
Right arrow Articles by Wadstedt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carlsson, L.
Right arrow Articles by Wadstedt, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Arrhythmia
Hazardous Substances DB
*CISAPRIDE

Vol. 282, Issue 1, 220-227, 1997

Electrophysiological Characterization of the Prokinetic Agents Cisapride and Mosapride in Vivo and in Vitro: Implications for Proarrhythmic Potential?

Leif Carlsson, Gregory J Amos, Birgit Andersson, Lissen Drews, Göran Duker and Gunilla Wadstedt

Astra Hässle AB, Preclinical Research & Development, Cardiovascular Pharmacology, S-431 83 Mölndal, Sweden

In the present study the electrophysiological characteristics and the proarrhythmic potential of cisapride and a structurally related drug, mosapride, were compared. In the anesthetized guinea pig, cisapride and d-sotalol (0.01-10 µmol/kg i.v., n = 6) dose-dependently prolonged the duration of the monophasic action potential recorded from the left ventricle. The maximal lengthening was 18 ± 3.2% at 1.0 µmol/kg (mean ± S.E.M., P < .01 vs. base line) and 19 ± 2.5% at 10 µmol/kg (P < .001) for cisapride and d-sotalol, respectively. In contrast, mosapride did not increase this variable. In a rabbit model of the acquired long QT syndrome, infusion of cisapride (0.3 µmol/kg/min for 10 min maximum, n = 6), but not mosapride or vehicle, was associated with a significant lengthening of the QTU interval (43 ± 3.8 ms, P < .01). Furthermore, torsades de pointes appeared in two of the six rabbits given cisapride. In isolated rabbit Purkinje fibers (PF), cisapride increased the action potential duration (48 ± 5.6% at 0.1 µmol/l, P < .01 vs. control, n = 4). Mosapride did not significantly influence the action potential duration (3 ± 2.0% increase at 1.0 µmol/l, n = 6). However, after mosapride was washed out, the addition of cisapride (0.1 µmol/l) caused a 46 ± 3.2% lengthening of the action potential duration (P < .01 vs. 1.0 µmol/l mosapride). Early afterdepolarizations and triggered activity appeared in four of eight cisapride-superfused PF stimulated at a very low frequency (0.1 Hz). In isolated rabbit cardiomyocytes, cisapride concentration-dependently blocked (IC50 = 9 nmol/l) the rapid component of the delayed rectifying K+ current (IKr). Mosapride was approximately 1000-fold less potent in blocking IKr (IC50 = 4 µmol/l). It is concluded that the electrophysiological characteristics of cisapride may explain the recently reported propensity to prolong the QT interval and to induce torsades de pointes in susceptible patients, although a structurally related benzamide, mosapride, did not appear to have electrophysiological features of relevance for induction of torsades de pointes in common with cisapride.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Toxicol SciHome page
B. D. Guth
Preclinical Cardiovascular Risk Assessment in Modern Drug Development
Toxicol. Sci., May 1, 2007; 97(1): 4 - 20.
[Full Text] [PDF]

Home page
 Toxicol SciHome page
A. Kijtawornrat, Y. Nishijima, B. M. Roche, B. W. Keene, and R. L. Hamlin
Use of a Failing Rabbit Heart as a Model to Predict Torsadogenicity
Toxicol. Sci., September 1, 2006; 93(1): 205 - 212.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
F De Ponti
Pharmacology of serotonin: what a clinician should know
Gut, October 1, 2004; 53(10): 1520 - 1535.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Potet, T. Bouyssou, D. Escande, and I. Baro
Gastrointestinal Prokinetic Drugs have Different Affinity for the Human Cardiac Human Ether-a-gogo K+ Channel
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1007 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. E. M. Vickers, M. Zollinger, R. Dannecker, R. Tynes, F. Heitz, and V. Fischer
In Vitro Metabolism of Tegaserod in Human Liver and Intestine: Assessment of Drug Interactions
Drug Metab. Dispos., October 1, 2001; 29(10): 1269 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
B. Darpo
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
L. Carlsson
Drug-induced torsade de pointes: the perspectives of industry
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K114 - K120.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Desta, N. Soukhova, A. M Morocho, and D. A Flockhart
Stereoselective Metabolism of Cisapride and Enantiomer-Enantiomer Interaction in Human Cytochrome P450 Enzymes: Major Role of CYP3A
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 508 - 520.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Benatar, A. Feenstra, T. Decraene, and Y. Vandenplas
Effects of Cisapride on Corrected QT Interval, Heart Rate, and Rhythm in Infants Undergoing Polysomnography
Pediatrics, December 1, 2000; 106(6): 85e - 85.
[Abstract] [Full Text]

Home page
 Eur Heart JHome page
W Haverkamp, G Breithardt, A.J Camm, M.J Janse, M.R Rosen, C Antzelevitch, D Escande, M Franz, M Malik, A Moss, et al.
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology
Eur. Heart J., August 1, 2000; 21(15): 1216 - 1231.
[PDF]

Home page
 Cardiovasc ResHome page
W. Haverkamp, G. Breithardt, A.J. Camm, M. J Janse, M. R Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, et al.
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology
Cardiovasc Res, August 1, 2000; 47(2): 219 - 233.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Z. Desta, N. Soukhova, S. K. Mahal, and D. A. Flockhart
Interaction of Cisapride with the Human Cytochrome P450 System: Metabolism and Inhibition Studies
Drug Metab. Dispos., July 1, 2000; 28(7): 789 - 800.
[Abstract] [Full Text]

Home page
 PediatricsHome page
A. Benatar, A. Feenstra, T. Decraene, Y. Vandenplas;, S. L. Hill, and C. Berul
Cisapride and Proarrhythmia in Childhood
Pediatrics, April 1, 1999; 103(4): 856 - 856.
[Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Crema, C. Modini, T. Croci, M. Langlois, and F. de Ponti
Intestinal Prokinesia by Two Esters of 4-Amino-5-Chloro-2-Methoxybenzoic Acid: Involvement of 5-Hydroxytryptamine-4 Receptors and Dissociation from Cardiac Effects In Vivo
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1045 - 1052.
[Abstract] [Full Text]

Home page
 PediatricsHome page
R. M. Ward, J. A. Lemons, and R. A. Molteni
Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns
Pediatrics, February 1, 1999; 103(2): 469 - 472.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.